Department of Internal Medicine III, University Hospital of Ulm, Ulm, 89081, Germany.
Department of Internal Medicine II, Hematology and Oncology, Friedrich-Schiller-University Medical Center, Jena, 07743, Germany.
Nat Commun. 2019 May 2;10(1):2031. doi: 10.1038/s41467-019-09745-2.
Mutations in the nucleophosmin 1 (NPM1) gene are considered founder mutations in the pathogenesis of acute myeloid leukemia (AML). To characterize the genetic composition of NPM1 mutated (NPM1) AML, we assess mutation status of five recurrently mutated oncogenes in 129 paired NPM1 samples obtained at diagnosis and relapse. We find a substantial shift in the genetic pattern from diagnosis to relapse including NPM1 loss (n = 11). To better understand these NPM1 loss cases, we perform whole exome sequencing (WES) and RNA-Seq. At the time of relapse, NPM1 loss patients (pts) feature distinct mutational patterns that share almost no somatic mutation with the corresponding diagnosis sample and impact different signaling pathways. In contrast, profiles of pts with persistent NPM1 are reflected by a high overlap of mutations between diagnosis and relapse. Our findings confirm that relapse often originates from persistent leukemic clones, though NPM1 loss cases suggest a second "de novo" or treatment-associated AML (tAML) as alternative cause of relapse.
核磷蛋白 1(NPM1)基因突变被认为是急性髓系白血病(AML)发病机制中的创始性突变。为了研究 NPM1 突变(NPM1)AML 的遗传组成,我们评估了在诊断和复发时获得的 129 对 NPM1 样本中五个反复突变的致癌基因的突变状态。我们发现,从诊断到复发,遗传模式发生了很大变化,包括 NPM1 缺失(n=11)。为了更好地理解这些 NPM1 缺失病例,我们进行了全外显子组测序(WES)和 RNA-Seq。在复发时,NPM1 缺失患者(pts)具有独特的突变模式,与相应的诊断样本几乎没有体细胞突变,并且影响不同的信号通路。相比之下,NPM1 持续存在的 pts 特征是诊断和复发之间的突变高度重叠。我们的研究结果证实,复发通常源于持续存在的白血病克隆,但 NPM1 缺失病例提示存在第二种“从头发生”或治疗相关 AML(tAML)作为复发的替代原因。